Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Therapeutic targeting of Chronic Kidney Disease-associated DAMPs differentially contributing to vascular pathology. [atherosclerosis AAN+Paquinimod aortas]
PubMed Full text in PMC Similar studies
Therapeutic targeting of Chronic Kidney Disease-associated DAMPs differentially contributing to vascular pathology.
Therapeutic targeting of Chronic Kidney Disease-associated DAMPs differentially contributing to vascular pathology. [atherosclerosis AAN+PaqusTLR2 blood]
Therapeutic targeting of Chronic Kidney Disease-associated DAMPs differentially contributing to vascular pathology. [atherosclerosis AAN+sTLR2 aortas]
Calprotectin blockade inhibits long-term vascular pathology following peritoneal dialysis-associated bacterial infection.
Calprotectin blockade inhibits long-term vascular pathology following peritoneal dialysis-associated bacterial infection. [2]
Calprotectin blockade inhibits long-term vascular pathology following peritoneal dialysis-associated bacterial infection. [1]
Chronic kidney disease is characterized by expansion of pro-inflammatory, HLA-DR-high intermediate monocytes and by increased monocyte adhesion to endothelial cells
PubMed Full text in PMC Similar studies SRA Run Selector
Downregulation of HDAC9 by β-hydroxybutyrate suppresses vascular calcification in chronic kidney disease
PubMed Similar studies Analyze with GEO2RSRA Run Selector
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on